Reviewed by Peptide Treatments Medical Advisory Board
Livagen: Research & Evidence
Early-Stage ResearchPublished research, clinical trial data, and evidence grading for Livagen across studied indications.
Back to Livagen overviewResearch Summary
Livagen has zero PubMed-indexed human studies, zero RCTs, and no Western clinical trials. All efficacy claims derive from Russian-language animal studies that have not been independently replicated. Established hepatoprotectants like silymarin and N-acetylcysteine have considerably more human evidence.
Evidence by Indication (2 indications)
| Indication | Tier | Trials | Summary |
|---|---|---|---|
| Liver protection | Tier D | 0 | No human trials exist; rodent studies report hepatocyte protection from toxins but remain unverified |
| Liver regeneration | Tier D | 0 | Animal data suggests hepatocyte proliferation effects but no human translation has been attempted |
Graded using our evidence tier methodology.
Research Gap Score /10
Higher score = larger gap between therapeutic potential and available clinical evidence.